Low-Dose Anticholinergic Combination Therapy in Male Benign Prostatic Hyperplasia Patients with Overactive Bladder Symptoms

• Published in: Lower urinary tract symptoms Vol. 4; no. s1; pp. 102 - 109
• Main Authors: PARK, Won Hee, GON KIM, Hyeong
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01-03-2012; Wiley Subscription Services, Inc
• Subjects: anticholinergic drug; benign prostatic hyperplasia; Bladder; Drug therapy; low dose; overactive bladder; Prostate; Urinary incontinence; anticholinergic drug; low dose; overactive bladder; benign prostatic hyperplasia
• ISSN: 1757-5664; 1757-5672
• DOI: 10.1111/j.1757-5672.2011.00135.x

Most men with lower urinary tract symptoms have both storage and voiding symptoms. Overactive bladder symptoms occur in 50–75% of men with benign prostatic obstruction. Alpha‐blockers are usually the first option in medical therapy. Even though voiding symptoms are alleviated by the use of medicines or transurethral resection of the prostate, storage symptoms continue in 30–65% of patients. Combination therapy with an alpha1‐receptor antagonist and an anticholinergic agent in benign prostatic hyperplasia patients with overactive bladder symptoms significantly alleviates symptoms and improves quality of life. In clinical practice, the efficacy and safety of anticholinergic combination therapy may not be comparable with well‐controlled studies. Overactive bladder symptoms usually require long‐term treatment, and benign prostatic hyperplasia tends to progress with time. When male LUTS patients are treated with anticholinergic combination therapy, there are still some concerns about the development of acute urinary retention, voiding difficulty, and other anticholinergic side‐effects. If the drug is prescribed in a relatively low dosage, however, this approach could be appealing regarding adverse effects. There is a relatively small number of clinical reports about low‐dose combination therapy, which is in its early stages. Promising results are being reported, though the level of evidence is low. We await the final results.